Toward Better Drug Repositioning: Prioritizing and Integrating Existing Methods Into Efficient Pipelines

Drug Discov Today. 2014 May;19(5):637-44. doi: 10.1016/j.drudis.2013.11.005. Epub 2013 Nov 14.

Abstract

Recycling old drugs, rescuing shelved drugs and extending patents' lives make drug repositioning an attractive form of drug discovery. Drug repositioning accounts for approximately 30% of the newly US Food and Drug Administration (FDA)-approved drugs and vaccines in recent years. The prevalence of drug-repositioning studies has resulted in a variety of innovative computational methods for the identification of new opportunities for the use of old drugs. Questions often arise from customizing or optimizing these methods into efficient drug-repositioning pipelines for alternative applications. It requires a comprehensive understanding of the available methods gained by evaluating both biological and pharmaceutical knowledge and the elucidated mechanism-of-action of drugs. Here, we provide guidance for prioritizing and integrating drug-repositioning methods for specific drug-repositioning pipelines.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems / methods
  • Drug Delivery Systems / trends
  • Drug Discovery / methods*
  • Drug Discovery / trends*
  • Drug Evaluation, Preclinical / methods
  • Drug Evaluation, Preclinical / trends
  • Drug Repositioning / methods*
  • Drug Repositioning / trends*
  • Humans